Proceedings · Session S-564 · filed November 19, 2026

Lab Technology & MethodsSession paper

CRISPR Screens in 261 Stem Cell Lines Link Alzheimer's Variants to Microglia Function

Researchers derived microglia from 261 iPSC lines and used CRISPR knockout of 251 genes to connect neurodegenerative risk variants to cell movement and debris clearance, published in Nature Genetics.

By Priya Raman3 min read693 words

Summary

  • Researchers used 261 human iPSC lines to derive microglia-like cells and connect genetic variants to cell behavior, published in Nature Genetics.
  • eQTL analysis identified 7,121 associated genes and 79 colocalizations across four neurodegenerative disease GWAS.
  • CRISPR screens knocked out 251 disease-relevant genes; TREM2 knockout increased phagocytosis in microglia but decreased it in macrophages.
  • 34 genes were mapped to changes in cell behavior through lab tests and computational modeling.
  • Co-senior authors are Andrew Bassett and Gosia Trynka of the Wellcome Sanger Institute and Open Targets.
CRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk
FigureCRISPR Screening Reveals How Genetic Variants Drive Neurodegenerative Risk — KC_Woon / pixabay

Researchers at the Wellcome Sanger Institute and Open Targets have used 261 human induced pluripotent stem cell (iPSC) lines, quantitative trait locus mapping and CRISPR knockout screens to connect neurodegenerative risk variants to measurable changes in brain immune cell behavior. The study, published in Nature Genetics under the title "Integrated QTL mapping and CRISPR screening in pooled iPSC-derived microglia reveals genetic drivers of neurodegenerative risk," maps 34 genes to changes in cell function and knocks out 251 disease-relevant genes to test their effects.

Why the translational gap matters

Genome-wide association studies have identified thousands of variants linked to complex diseases, yet most are non-coding and probably act by regulating gene expression in specific cell types, states or environments. As the authors wrote, "translating these into biological insight remains challenging." Around a hundred genomic regions have been linked to Alzheimer's disease alone, but pinpointing the exact genes involved and how they alter cell behavior has proven difficult.

The team attacked this problem in microglia, specialized immune cells that move through the brain and clear cellular debris and misfolded proteins through phagocytosis, a process essential for healthy neuronal function. Microglia are effectively inaccessible for sampling in living patients, which has hindered direct study of disease-associated variants in these cells.

What did the framework measure?

The researchers differentiated iPSCs from hundreds of donors into microglia-like (iMGL) cells and worked through three stages:

  • eQTL analysis to identify which genetic variants change gene levels in microglia, yielding 7,121 eQTL-associated genes and 79 colocalizations across four neurodegenerative disease GWAS — Alzheimer's, Parkinson's, multiple sclerosis and ALS. Half of these colocalizations had limited prior evidence of causality.
  • Functional assays measuring cell movement and phagocytosis, combined with computational modeling, to map 34 genes to changes in cell behavior. This analysis highlighted disease-relevant variants at TREM2 linked to altered phagocytosis.
  • CRISPR screens knocking out 251 disease-relevant genes to probe how each affects microglia behavior.

Co-senior author Andrew Bassett, PhD, said: "By growing brain immune cells from stem cells across hundreds of donors, we've built a framework that directly connects genetic risk to real cell functions, such as how effectively these cells clear debris in the brain."

Why does cellular context change the answer?

The CRISPR screens produced a result with direct implications for target selection: the effect of a genetic mutation can reverse depending on cell type and environment. Knocking out TREM2 increased phagocytosis in microglia but decreased it in macrophages, a different immune cell type.

"These results demonstrate that modulation of TREM2 leads to different phenotypic outcomes depending on the cell type, and emphasize the importance of cellular context when interpreting its function in neurodegeneration," the authors stated. For R&D teams evaluating microglia-targeted programs, the finding argues against interpreting variant effects from a single cell model.

Bassett put it bluntly: "We also discovered that the impact of a genetic variant can change depending on its cellular environment, in some cases having the opposite effect. This suggests that we can't just look at the impact of these genetic changes in isolation or in one cell."

What are the limits and the next steps?

The study measured gene expression, cell survival, movement and phagocytosis in iPSC-derived cells under different inflammatory stimulation conditions — a model system, not primary human tissue. Co-first author Marta Perez-Alcantara, PhD, previously at the Wellcome Sanger Institute and Open Targets, noted the approach's value for difficult-to-access tissues such as the brain, where primary microglia are hard to obtain in sufficient numbers and under the right stimuli. She added that the framework could extend to other diseases, tissues or cellular phenotypes.

Co-senior author Gosia Trynka, PhD, Science Director at Open Targets, framed the payoff for portfolio decisions: "Connecting this allows us to start to build a full biological picture of disease and will help design future research to accelerate drug discovery."

The authors conclude that integrating genetic association data, single-cell transcriptomics and pooled functional genomics makes genotype–phenotype investigation feasible at scale — and state that the framework applies to other cell types and diseases beyond neurodegeneration.

via doi.org (Original)

Filed under

  • crispr-screening
  • ipsc-derived-microglia
  • alzheimer-s-disease
  • qtl-mapping
  • microglial-phagocytosis
Share this article:

More from Priya Raman

Priya Raman

Show full bio

Staff writer covering money, funding and market shifts around research and development at Hypothesis Wire.

283 articles

References

  1. APOE4 Vascular Damage in Alzheimer's Shown Reversible in Mouse Models
  2. Oral TREM2 Agonist Safe in 115-Person Phase I, Protects Neurons in Mice
  3. Two injections reversed Alzheimer's pathology in mice via neuron reprogramming
  4. David Liu advances disease-agnostic gene editing at ESGCT
  5. Mouse atlas identifies 92 protective proteins crossing brain barrier

« Previous article